ESTRELLA IMMUNOPHARMA, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-18
- ESTRELLA IMMUNOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -0.70%.
- ESTRELLA IMMUNOPHARMA, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2025-12-31 | -0.70% 10-K · filed 2026-03-18 |
| 2024-12-31 | -0.90% 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |